Formycon AG (CHIX:FYBD) Valuation Rank


CHIX:FYBD Formycon AG CHIX:FYBD
60 GF Score
Price €63.30
GF Value €120.94
! 5 Warning Signs
View Full Analysis

What is Formycon AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Formycon AG Valuation Rank Related Terms

CHIX:FYBD
60GF Score
Formycon AG CHIX:FYBD
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Formycon AG (CHIX:FYBD) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €63.30 is trading 47.7% below its estimated GF Value™ of €120.94.

Key valuation signals for CHIX:FYBD:

  • Valuation Rank:
  • GF Value™: €120.94 vs. price of €63.30 (47.7% below fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the CHIX:FYBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formycon AG Business Description

Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
60GF Score

Get the complete analysis for CHIX:FYBD

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€63.30
Price
€120.94
GF Value